Profile data is unavailable for this security.
About the company
Jiang Zhong Pharmaceutical Co Ltd is a China-based company mainly engaged in the pharmaceutical manufacturing industry. The Company's products are classified into over-the-counter drugs, prescription drugs, big health products and others, covering the fields of spleen and stomach, intestines, throat, tonic, rehabilitation nutrition, high-end tonic, cardiovascular and cerebrovascular, gynecology, urinary system and others OTC products include Jianweixiaoshi Tablets, Lactobacillus Tablets, Compound Coral Grass Tablets, and Bifidobacterium Triple Live Enteric Capsules. Health products mainly include peptides and protein powder products. Prescription drug products include Chinese medicine products such as Bazhen Yimu Capsules, Shenbao Capsules, Paishi Granules, Huangqi Shengmai Yin, Zhenju Jiangya Tablets, Shuangju Granules, Zhikang Tablets, Shuxiong Granules and others
- Revenue in CNY (TTM)4.22bn
- Net income in CNY753.16m
- Incorporated1996
- Employees4.01k
- LocationJiang Zhong Pharmaceutical Co LtdNo. 788, Huoju Avenue, High-Tech ZoneNANCHANG 330096ChinaCHN
- Phone+86 79 188169323
- Fax+86 79 188162532
- Websitehttps://www.jzjt.com/
More ▼
Mergers & acquisitions
| Acquired company | 600750:SHH since announced | Transaction value |
|---|---|---|
| Jiangxi Jiangzhong Traditional Chinese Medicine Decoction Pieces Co Ltd | -18.37% | 12.10m |
| Jiangxi Jiangzhong Changrun Pharmaceutical Co Ltd | -14.02% | 830.00k |
| Jiangxi Jiangzhong Herbal Health Technology Co Ltd | -14.02% | 1.06m |
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Henan Lingrui Pharmaceutical Co., Ltd. | 3.56bn | 675.80m | 12.36bn | 2.53k | 18.16 | 4.27 | -- | 3.47 | 1.20 | 1.20 | 6.34 | 5.10 | 0.7489 | 2.24 | 10.18 | 1,408,620.00 | 14.20 | 10.68 | 23.52 | 16.56 | 72.35 | 74.42 | 18.96 | 14.92 | 0.9579 | -- | 0.0073 | 72.80 | 10.31 | 10.03 | 22.09 | 18.49 | -16.47 | 39.77 |
| Zhejiang CONBA Pharmaceutical Co., Ltd. | 6.46bn | 486.79m | 12.49bn | 8.41k | 25.42 | 1.88 | -- | 1.93 | 0.1912 | 0.1912 | 2.54 | 2.59 | 0.618 | 2.39 | 4.56 | 768,224.60 | 4.98 | 6.77 | 6.93 | 10.50 | 51.47 | 63.24 | 8.06 | 11.10 | 1.24 | -- | 0.0781 | 42.32 | 12.20 | -0.8267 | 65.20 | -6.21 | -11.64 | 5.92 |
| Tibet Rhodiola Pharmaceutical Holding Co | 2.94bn | 737.44m | 12.58bn | 601.00 | 15.14 | 3.47 | -- | 4.28 | 2.58 | 2.58 | 9.69 | 11.26 | 0.6264 | 1.54 | 6.79 | 4,894,779.00 | 15.80 | 12.44 | 20.83 | 15.71 | 93.36 | 90.51 | 25.22 | 20.43 | 3.44 | 7.74 | 0.1264 | 50.41 | 22.69 | 24.98 | 116.56 | 30.01 | -1.48 | 48.97 |
| BrightGene Bio-Medical Technology Co Ltd | 1.24bn | 188.08m | 12.69bn | 1.16k | 67.24 | 5.39 | -- | 10.22 | 0.4466 | 0.4466 | 2.96 | 5.57 | 0.2522 | 1.63 | 3.50 | 1,074,862.00 | 2.91 | 6.53 | 3.57 | 7.93 | 54.97 | 56.93 | 11.55 | 19.90 | 1.18 | 4.53 | 0.4841 | 29.31 | 15.94 | 23.68 | -15.51 | 22.56 | 29.13 | -- |
| Jiang Zhong Pharmaceutical Co Ltd | 4.22bn | 753.16m | 13.51bn | 4.01k | 17.90 | 3.63 | -- | 3.20 | 1.20 | 1.20 | 6.71 | 5.91 | 0.6828 | 3.58 | 15.12 | 1,052,061.00 | 13.36 | 10.82 | 20.72 | 15.08 | 63.72 | 65.02 | 19.56 | 18.17 | 0.8833 | -- | 0.0004 | 82.88 | 13.00 | 20.12 | 18.40 | 8.54 | 11.47 | 40.99 |
| Zhejiang Jiuzhou Pharmaceutical Co Ltd | 4.91bn | 697.36m | 14.59bn | 4.88k | 20.93 | 1.71 | -- | 2.97 | 0.7749 | 0.7749 | 5.45 | 9.51 | 0.4405 | 1.75 | 4.20 | 1,007,191.00 | 6.28 | 10.10 | 7.67 | 13.69 | 32.61 | 34.64 | 14.25 | 16.26 | 2.48 | -- | 0.0909 | 40.79 | 1.44 | 24.29 | 12.20 | 45.74 | 32.14 | 20.11 |
| Chongqing Taiji Industry Group Co Ltd | 13.87bn | 609.10m | 14.84bn | 12.59k | 24.36 | 3.71 | -- | 1.07 | 1.09 | 1.09 | 24.91 | 7.18 | 0.9696 | 2.82 | 5.08 | 1,102,051.00 | 4.46 | 0.7814 | 12.44 | 2.35 | 42.31 | 44.03 | 4.60 | 0.8498 | 0.4665 | 5.50 | 0.5528 | 25.76 | 10.58 | 7.88 | 131.99 | 63.55 | 3.86 | 24.57 |
Data as of Sep 13 2024. Currency figures normalised to Jiang Zhong Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
15.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Fund Management Co., Ltd.as of 30 Sep 2023 | 34.50m | 5.53% |
| China Investment Corp. (Investment Management)as of 30 Sep 2023 | 15.55m | 2.49% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 14.64m | 2.35% |
| Ping An Fund Management Co., Ltd.as of 30 Sep 2023 | 7.83m | 1.26% |
| First Seafront Fund Management Co., Ltd.as of 30 Jun 2024 | 7.18m | 1.15% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2024 | 5.31m | 0.85% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 3.62m | 0.58% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 2.18m | 0.35% |
| Baoying Fund Management Co., Ltd.as of 30 Jun 2024 | 2.06m | 0.33% |
| Orient Securities Asset Management Co. Ltd.as of 30 Jun 2024 | 1.84m | 0.30% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
